Table 1. Summary of in vivo pediatric tumor model studies.

Model	Xenograft type	Tumor type	Analysis day	Chemotherapy		DC101	Chemo	Combination	Combination effect^
				Agent	Dose, Schedule	% ΔT/C or regression on analysis day
SJCRH30	CDX	alveolar RMS	38	Doxorubicin	5 mg/kg, Q7Dx4	26	57	15†‡	Additive
RD	CDX	embryonal RMS	64	Doxorubicin	5 mg/kg, Q7Dx4	40	20	12†	Less than additive
CTG-1213	PDX	embryonal RMS	26	Actinomycin D	0.25 mg/kg, D0, 21	46	62	27‡	Unknown
CTG-0926	PDX	DSRCT	28	Doxorubicin	5 mg/kg, Q7Dx4	60	42	22†‡	Unknown
CTG-1458	PDX	DSRCT	35	Cyclophosphamide	100 mg/kg, Q7Dx4	50	42	8†‡	Additive
RD-ES	CDX	Ewing’s sarcoma	28	Doxorubicin	5 mg/kg, Q7Dx4	69	28	-30†‡	Additive
CTG-0142	PDX	Ewing’s sarcoma	28	Doxorubicin	5 mg/kg, Q7Dx4	44	38	11†‡	Unknown
CTG-0785	PDX	Ewing’s sarcoma	18	Doxorubicin	5 mg/kg, Q7Dx4	37	46	41	Less than additive
CTG-0816	PDX	Ewing’s sarcoma	35	Doxorubicin	5 mg/kg, Q7Dx4	3	3	-49†‡	Less than additive
CTG-0994	PDX	Ewing’s sarcoma	21	Doxorubicin	5 mg/kg, Q7Dx4	19	78	42‡	Less than additive
CTG-1072	PDX	hepatoblastoma	17	Cisplatin	5 mg/kg, Q7Dx4	55	55	52	No effect
A-204	CDX	malignant rhabdoid tumor	52	Doxorubicin	5 mg/kg, Q7Dx4	62	33	31	No effect
IMR-32	CDX	neuroblastoma	70	Doxorubicin	3 mg/kg, Q7Dx4	47	30	16†‡	Additive
KELLY	CDX	neuroblastoma	49	Doxorubicin	2 mg/kg, Q7Dx3	46	98	48‡	No effect
SH-SY5Y	CDX	neuroblastoma	52	Doxorubicin	5 mg/kg, Q7Dx4	25	10	-28	No effect
CTG-0241	PDX	osteosarcoma	28	Doxorubicin	5 mg/kg, Q7Dx4	51	109	78	No effect
CTG-0242	PDX	osteosarcoma	28	Doxorubicin	5 mg/kg, Q7Dx4	56	9	21	No effect
CTG-0243	PDX	osteosarcoma	16	Doxorubicin	5 mg/kg, Q7Dx4	229	219	95†‡	No effect
CTG-1064	PDX	osteosarcoma	27	Doxorubicin	5 mg/kg, Q7Dx4	53	157	41‡	No effect
Y79	CDX	retinoblastoma	44	Doxorubicin	5 mg/kg, Q7Dx4	16	18	-11	Unknown
CTG-0331	PDX	synovial sarcoma	27	Doxorubicin	5 mg/kg, Q7Dx4	22	36	7‡	No effect
CTG-1173	PDX	synovial sarcoma	52	Gemcitabine Docetaxel	60 mg/kg, Q7Dx4 6 mg/kg, Q7Dx4	79	-43	-64†‡	Additive
CTG-1094	PDX	undifferentiated sarcoma	17	Doxorubicin	5 mg/kg, Q7Dx4	45	44	53	No effect

p < 0.05 compared to control

^BLISS independence method

^† p < 0.05 compared to DC101 alone

^‡ p < 0.05 compared to chemotherapy alone